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Background
The bisphosphonates are a group of products
that are effective in the prevention and treatment
of postmenopausal and glucocorticoid-induced
osteoporosis and also Paget’s disease. They
increase bone density by binding to the surfaces of
bones and slow down osteoclastic activity,
thereby facilitating osteoblastic effectiveness.
Alendronate (Fosamax) and risedronate (Actonel)
are commonly prescribed bisphosphonate agents.
The most common side effect of the
bisphosphonates is gastrointestinal upset. This is
often dose-related.1-3
Post-marketing surveillance data from several
countries are revealing severe bone, joint, and
muscle pain associated with these agents,
specifically alendronate and risedronate.4-7

Reported Events
Since the marketing of Fosamax in the US
beginning September 1995 up to November 2002,
there have been 118 reports of severe bone, joint,
and/or muscle pain in patients. Ninety-six percent
of these events occurred in women. Of those
cases for which sufficient information was
provided, 74% occurred at a daily dose of 10 mg
and 18% occurred with a once-weekly dosage of
70 mg. Pain onset ranged from the same day to
52 months with an average of 14 days from
therapy start. In some patients, pain initiated in
one site then migrated and became diffuse. Pain
was severe enough to require bedrest, walkers, or
crutches and resulted in inability to perform usual
activities for some patients. Opioids, ketorolac
(Toradol), or other agents were used to treat the
pain. In 66% of the patients, Fosamax was
discontinued; some experienced immediate relief
but most had gradual improvement. Eleven
percent of the patients for whom therapy was
discontinued redeveloped pain after therapy
restart.4

Post-marketing surveillance data for Actonel
from its marketing in September 1998 through
June 2003 have revealed six severe cases of bone,
joint, or muscle pain. Specific demographic,
epidemiologic, or dosage data have not been
published at this time.4
The Australian Adverse Drug Reactions
Advisory Committee has received 61 reports of
musculoskeletal adverse events since the 1996
marketing of Fosamax there. Of these 61 cases,
35 reported muscle pain, 29 identified joint pain,
six were associated with bone pain, and ten cases
had mixed muscle and joint pain. Onset of pain
ranged from the start day to over one year of
therapy. Pain recurred in 13% of those rechallenged with the drug.5
Data from the Canadian Adverse Drug
Reaction Monitoring Program for the time period
of December 1995 to January 1998 identified two
cases of alendronate-associated musculoskeletal
pain from a total of 138 reports. One case
involved exacerbation of rheumatoid arthritis with
accompanying gastrointestinal complaints in a 64
year old woman after receiving alendronate 10 mg
daily for four weeks.6
In a study of alendronate-associated
esophageal reaction incidence by Mackay et al,
the researchers used a calculated incidence density
for reporting events.
In their study period
nausea/vomiting incidence was 8.3, dyspepsia
incidence was 11.3, abdominal pain incidence was
7.5, back pain incidence was 5.3, and joint pain
incidence was 4.1.7

Commentary
These data suggest an association of
bisphosphonate-related musculoskeletal pain.
However, there is no specific baseline data on the
incidence of existing musculoskeletal conditions
in these patients.
This makes the clinical
significance of these observations difficult to
determine. Furthermore, underreporting of these
More. . .
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musculoskeletal adverse events may occur due to
confusion of drug-related vs disease-related
conditions such as pre-existing osteoporosis or
osteoarthritis. It is interesting to note that in the
therapy discontinuation cases mentioned above,
pain reoccurred with bisphosphonate rechallenge
in only 11 to 13% of recorded cases.4,5
Newly reported cases of musculoskeletal pain
following initial or prolonged treatment with
bisphosphonate agents should be checked. A
bisphosphonate discontinuation trial may be
initiated to potentially determine an association
when other causes of pain have been ruled-out.
Other non-bisphosphonate agents that may be
used for osteoporosis include estrogen
replacement (based on the individual woman’s
history and risk factors and used for the shortest
period at the lowest possible dose), raloxifene
(Evista), calcitonin (Miacalcin), and synthetic
parathyroid hormone (Forteo). Adequate calcium
and vitamin D are essential supplements but not
adequate alone for treatment.1,2
Encourage reporting of suspected adverse drug
events. To report adverse events in the US, call
the FDA MEDWATCH program at 1-800-FDA1088. The MEDWATCH program is also
available on-line at www.fda.gov/medwatch. In
Canada, call the Canadian Adverse Drug Reaction
Monitoring Program at 1-866-234-2345. The
Canadian adverse reaction reporting form can be
found at: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpddpt/adverse_e.pdf. It should be completed and
faxed to 1-866-678-6789.

judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
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